Robert W. Baird upgraded shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from a neutral rating to an outperform rating in a report published on Monday, MarketBeat reports. Robert W. Baird currently has $150.00 price target on the biopharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on ALXN. Credit Suisse Group reaffirmed a buy rating and set a $166.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, December 12th. Leerink Swann reaffirmed a buy rating and set a $169.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday, December 6th. BidaskClub raised Alexion Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Sunday, August 20th. BMO Capital Markets reaffirmed an outperform rating and set a $173.00 price target (up from $168.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Finally, SunTrust Banks restated a buy rating and set a $180.00 target price (up from $170.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $155.70.

Shares of Alexion Pharmaceuticals (NASDAQ ALXN) opened at $118.35 on Monday. The firm has a market capitalization of $25,852.96, a PE ratio of 23.67, a price-to-earnings-growth ratio of 1.26 and a beta of 1.18. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, topping the consensus estimate of $1.32 by $0.12. The company had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period last year, the firm earned $1.23 EPS. equities analysts anticipate that Alexion Pharmaceuticals will post 4.82 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. lifted its stake in Alexion Pharmaceuticals by 7.0% in the 2nd quarter. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company’s stock valued at $2,424,428,000 after buying an additional 1,298,185 shares in the last quarter. Vanguard Group Inc. lifted its stake in Alexion Pharmaceuticals by 2.2% in the 2nd quarter. Vanguard Group Inc. now owns 14,785,831 shares of the biopharmaceutical company’s stock valued at $1,798,992,000 after buying an additional 318,375 shares in the last quarter. State Street Corp lifted its stake in Alexion Pharmaceuticals by 5.0% in the 2nd quarter. State Street Corp now owns 11,860,647 shares of the biopharmaceutical company’s stock valued at $1,443,099,000 after buying an additional 561,962 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in Alexion Pharmaceuticals by 3.5% in the 3rd quarter. Ameriprise Financial Inc. now owns 6,390,301 shares of the biopharmaceutical company’s stock valued at $896,491,000 after buying an additional 215,005 shares in the last quarter. Finally, Jennison Associates LLC lifted its stake in Alexion Pharmaceuticals by 720.0% in the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after buying an additional 4,682,336 shares in the last quarter. 94.26% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Alexion Pharmaceuticals (ALXN) Raised to “Outperform” at Robert W. Baird” was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/alexion-pharmaceuticals-alxn-raised-to-outperform-at-robert-w-baird/1775777.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.